Papers
(The TQCC of Immunotherapy is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
| Bimekizumab for The Treatment of Psoriasis | 5 |
| Beyond conventional therapies: immunotherapeutic strategies targeting HPV-associated cervical cancer | 5 |